48 129

Cited 0 times in

만성 폐쇄성 폐질환 환자에서 Tiotropium 1일 1회, 1회 18㎍ 요법과 Ipratropium 1일 4회, 1회 40㎍ 요법의 치료효과 및 안전성 비교

Other Titles
 A Comparison of Tiotropium 18㎍, Once Daily and Ipratropium 40㎍, 4 Times Daily in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults with Chronic Obstructive Pulmonary Disease 
 김승준  ;  김명숙  ;  이상학  ;  김영균  ;  문화식  ;  박성학  ;  이상엽  ;  인광호  ;  이창률  ;  김영삼  ;  김형중  ;  안철민  ;  김성규  ;  김경록  ;  차승익  ;  정태훈  ;  김미옥  ;  박성수  ;  최천웅  ;  유지홍  ;  강홍모  ;  고원중  ;  함형석  ;  강은혜  ;  권오정  ;  이양덕  ;  이흥범  ;  이용철  ;  이양근  ;  신원혁  ;  권성연  ;  김우진  ;  이철규  ;  김영환  ;  심영수  ;  한성구  ;  박혜경  ;  김윤성  ;  이민기  ;  박순규  ;  김미혜  ;  리원연  ;  용석중  ;  신계철  ;  최병휘  ;  오연목  ;  임채만  ;  이상도  ;  김우성  ;  김동순  ;  정성수  ;  김주옥  ;  고영춘  ;  김영철  ;  유남수 
 Tuberculosis and Respiratory Diseases, Vol.58(5) : 498-506, 2005 
Journal Title
 Tuberculosis and Respiratory Diseases 
Issue Date
Background : This study compared the bronchodilator efficacy and safety of tiotropium inhalation capsules (18㎍once daily) with a ipratropium metered dose inhaler (2 puffs of 20㎍ q.i.d.) in patients with chronic obstructive pulmonary disease (COPD). Method : After the initial screening assessment and a two-week run-in period, patients received either tiotropium 18㎍once daily or ipratropium 40㎍four times daily over a period of 4 weeks in a double blind, double dummy, parallel group study. The outcome measures were the lung function, the daily records of the peak expiratory flow rate (PEFR), the patients´ questionnaire, and the use of concomitant salbutamol. The forced expiratory volume in one second (FEV1) and the forced vital capacity (FVC) were measured 5 minutes before inhalation, and 0.5, 1, 2 and 3 hours after inhaling the study drug on days 0, 14 and 28. Result : In 16 centers, 134 patients with a mean (SD) age of 66 (7) years and a predicted FEV1 of 42 (12)% were analyzed. The trough FEV1 response was significantly higher in the tiotropium group than in the ipratropium group after a four-week treatment period. The weekly mean morning PEFR of the tiotropium group was consistently higher than that of the ipratropium group during the 4-week treatment period with differences ranging from 12.52 to 13.88l/min, which were statistically significant. Tiotropium was well tolerated by the COPD patients during the 4-week treatment period and had a similar safety profile to ipratropium. Conclusion : This study shows that tiotropium administrated once daily has a superior bronchodilator effect with a similar safety profile in treating COPD patients compared with ipratropium, inhaled four times daily.
Files in This Item:
T200501111.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Sung Kyu(김성규)
Kim, Young Sam(김영삼) ORCID logo https://orcid.org/0000-0001-9656-8482
Kim, Hyung Jung(김형중) ORCID logo https://orcid.org/0000-0003-2498-0683
Ahn, Chul Min(안철민)
RIS (EndNote)
XLS (Excel)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.